Conclusion: Therapeutic decision-making based on validated disease activity scales has allowed the BT optimization in approximately 53% of patients with RD. BT optimization allowed a pharmaceutical saving of € 177,539.40 per year being higher in the SA (€ 850.40) followed by the RA (€ 707.63) and finally the PsA (€ 493.21)

The BT optimization allows to reduce costs maintaining the effectiveness and safety.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5354

AB1151 COMPLIANCE/CONCORDANCE WITH MYCOPHENOLATE MOFETIL IN PATIENTS WITH CONNECTIVE TISSUE DISORDERS IN COVENTRY.

A. Chauhan¹, N. Lovell¹, S. Dubey¹. ¹Coventry and Warwickshire, Rheumatology, Coventry, United Kingdom

Background: Connective tissue disorders like Systemic lupus erythematosus (SLE) are multi-organ systemic conditions characterised by disordered immune function. Mycophenolate Mofetil (MMF) is commonly used for treatment of SLE¹ and other connective tissue disorders like Sjogren's syndrome, myositis and Scleroderma. Compliance with drugs remains a significant issue in management of these conditions and varying reports from across the world^{2,3} continue to show significant lack of concordance resulting in increased disease activity and damage.

Objectives: The aim of this study was to investigate the compliance/concordance specifically with MMF treatment among patients attending clinics at University Hospitals Coventry and Warwickshire NHS Trust (UHCW) with SLE and other connective tissue disorders.

Methods: Ethical approval was obtained through research and development department within the Trust. This is a retrospective study collating non-identifiable hospital pharmacy data in patients who requested the prescription for MMF drug between January 2015 and December 2018. Since MMF was required to be prescribed from the hospital (i.e. General practitioners within the region were unable to prescribe it), we have records for all prescriptions for these patients. We extracted information on sample size, frequency of prescription requested and length of follow up. Clinical data were obtained from paper and electronic notes of the patients. Data were analysed using the data analysis tool pack for linear regression, on Microsoft Excel package version 16.29.1.

Results: We recruited 144 patients into this study, (74%) of these are females. Age range for this group was 2-89 years, median age was 45 (±11.2) years with a mean (±SD) age of 35.6 (±11.2) years and a disease duration of 8.8 (±6.2) years. 73.1% were White British, the remaining included 8.3% Indian, 5.5% Pakistani, 2.7% Black British, 2% Caucasian, 2.1% Chinese, and 6.3% other. Overall, we had 54 patients with SLE and 90 Patients with other connective tissue disorders. Good compliance (81-100%) with MMF therapy was seen in 49 patients, (34%). Poor compliance (0-20%) was seen in 13 patients, (9%). We found a significant correlation between lack of compliance and risk of flares ($r = 0.25$, $p < 0.002$), displayed in Figure 1. We also found a significant difference in compliance patterns depending on diagnosis and also on age. SLE patients were 34% less compliant with MMF in comparison to other connective tissue disorders. Demographics suggested the degree of compliance increased with age. Patients between 40-69 years of age were 65% more compliant in comparison to the age 20-39 years ($p < 0.002$).

Conclusion: SLE and connective tissue disorder patients within Coventry continue to have issues relating to compliance/concordance with MMF treatment and this appears to be worse in patients with SLE and in the 20-39 years of age. These patients also appear to be getting flares hence, this remains a major problem in the management of these conditions.

References:

- [1] Gordon C, Amissah-Arthur MB, Gayed M et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. *Rheumatol* 2017; doi: 10.1093/rheumatology/kex286.
- [2] Alsowaida N, Alrasheed M, Mayet A, Alsowaida A and Omair M A. Medication adherence, depression and disease activity among patients with systemic lupus erythematosus. *Lupus* 2018, 27(2), 327-332. doi:10.1177/0961203317725585.
- [3] Chehab G, G M Sauer, J G Richter, R Brinks, R Willers, R Fischer-Betz, B Winkler-Rohlfing, and M Schneider. Medical Adherence in Patients with Systemic Lupus Erythematosus in Germany: Predictors and Reasons for Non-Adherence – a Cross-Sectional Analysis of the LuLa-Cohort." *Lupus* (September 2018),1652-60. doi:10.1177/0961203318785245.

Figure 1. Relationship Showing %Compliance and Risk of Flares

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6415

AB1152 INCREASED VACCINATION RATE AMONG PATIENTS UNDER BIOLOGICAL DMARDS AFTER INFECTIOUS RISK ASSESSMENT CLINIC

E. Cunha Santos¹, A. S. Pinto¹, S. P. Dinis¹, C. Quinaz², J. F. Ferreira^{1,3}, C. Vaz³. ¹ULS - Unidade de Saúde Local da Guarda, Rheumatology, Guarda, Portugal; ²ULS - Unidade de Saúde Local da Guarda, Infectious Diseases, Guarda, Portugal; ³Faculdade de Ciências da Saúde, Covilhã, Portugal

Background: Infectious complications are a major concern among immunosuppressed patients. In an attempt to ameliorate these, EULAR released an updated version of their recommendations for vaccinations in patients with rheumatic diseases. These should resonate even further, since our patients are deliberately immunosuppressed in order to achieve remission. In 2018, an Infectious Risk Assessment Clinic (IRAC) was created in our centre to address these issues and prepare patients for biological therapy. This work summarizes our experience.

Objectives: Compare vaccination rate among patients with rheumatic diseases under biological therapy before and after the clinic creation.

Methods: A retrospective observational study was conducted in our Rheumatology Department and IRAC, at Local Health Unit of Guarda. All patients under biological therapy followed in our department from 2010 to 2020 were chart reviewed. Sociodemographic and clinical features were collected: sex, age, rheumatic disease diagnosis, current biological treatment and their vaccination history. Studied vaccines were Pneumococcal 13-valent conjugate, Pneumococcal vaccine polyvalent, Influenza virus, Hepatitis A and B, Herpes Zoster and Tetanus/Diphtheria. Patient was considered vaccinated when the correct schedule was followed by the attending physician. If prescription was outside the stipulated timing, it was considered not vaccinated. Chi-square and Fisher's exact test were used to assess associations and $p < 0.05$ was considered statistically significant different.

Results: 65 patients were included, 41 (63.10%) were females, with a mean age of 52.38 ± 11.11 years. Diagnosis distribution is the following: rheumatoid arthritis (52.30%), axial spondylarthritis (26.20%), psoriatic arthritis (12.30%), peripheral spondylarthritis (6.20%), 1 (1.50%) patient with Sjögren Syndrome and 1 (1.50%) with systemic sclerosis. Most common drugs were anti-TNFα (64.60%), anti-JAK (15.40%), anti-IL17A (10.80%), anti-CD20 (7.70%) and anti-IL12/IL23 (1.50%). Of all patients, 24 (36.90%) attended IRAC before starting biological therapy. Table 1 shows prescribed vaccines in both groups and their associations.

Table 1. Prescribed vaccines in both groups ($p < 0.05$).

	IRAC attended	IRAC not attended	P
Pneumococcal 13-valent conjugate			0.24
Prescribed	23 (95.83%)	34 (82.93%)	
Not Prescribed	1	7	
Pneumococcal vaccine polyvalent			0.01
Prescribed	19 (79.17%)	19 (46.34%)	
Not Prescribed	5	22	
Influenza virus			<0.01
Prescribed	22 (91.67%)	12 (29.27%)	
Not Prescribed	2	29	
Hepatitis A			0.05
Prescribed	3 (12.50%)	0 (0.00%)	
Not Prescribed	21	41	
Hepatitis B			<0.01
Prescribed	12 (50.00%)	0 (0.00%)	
Not Prescribed	12	41	
Herpes Zoster			0.37
Prescribed	1 (4.17%)	0 (0.00%)	
Not Prescribed	23	41	
Tetanus/Diphtheria			0.14
Prescribed	3 (12.50%)	1 (2.44%)	
Not Prescribed	21	40	